Neogenomics Inc (NEO) Stock Price, Quote & News

Company Profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the pr...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 239 768 0600

Fax: 239 690 4237

Website: www.neogenomics.com

Address:

9490 NeoGenomics Way, Fort Myers, United States

Pavie99 May. 14 at 12:41 AM

$NEO donzo

0 · Reply

Kat_Harington May. 13 at 4:10 PM

$NEO inverse of market. If Nasdaq is up I know this will be down.

0 · Reply

EarningsInsider May. 12 at 2:45 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-neo-performance-materials-inc-stock-1/ $NEO Neo Performance Materials Earnings Trans

1 · Reply

proof851 May. 6 at 12:45 PM

$NEO long term holder

0 · Reply

OfficialStocktwitsUser May. 5 at 3:11 PM

$NEO RSI: 54.24, MACD: 0.1950 Vol: 0.50, MA20: 8.46, MA50: 8.45 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

GordoHLYK13 May. 1 at 9:07 PM

$GNS $HLYK $STUB $NEO Good luck everyone in your investments. These are mine with my fun money, separate from my Nationwide Pro account and FRS pension. $GNS 10k shares average $.2741 * Arbitration win: 7.4M shares returned + $8M cash * 2026 outlook: $20–$22M revenue, potential positive adjusted EBITDA * AI education expansion + “Space Capsule” rollout $STUB (StubHub) 3k shares average $6.25 * Q1 2026 earnings scheduled for May 13, 2026 (after close) * Expanding globally in Asia and Latin America $NEO (NeoGenomics) 3k shares $7.97 * Raised 2026 revenue guidance to ~$797–$803M * New cancer test (RaDaR ST MRD) targeting large market * New insurance coverage boosting demand $HLYK (HealthLynked) 8k shares $5.54 * Working toward NASDAQ listing via $7M offering * Launching AI healthcare assistant (ARi) for patient management Just sharing what I’m personally positioned in—nothing more.

0 · Reply

GordoHLYK13 May. 1 at 4:12 PM

$GNS $NEO $STUB My total gains so far in few weeks $GNS is just starting

0 · Reply

GordoHLYK13 May. 1 at 1:23 PM

$GNS check out Genius trying to be my Friday anchor next to $NEO and $STUB Pre market todays gains

0 · Reply

GordoHLYK13 Apr. 30 at 11:06 PM

$GNS I don’t trade ego or keep score on comment sections — I trade setups. I move on the same way every time: lock in profits when they’re there, rotate out of noise, and re-enter when I see asymmetric upside with real catalysts and structure behind it like $NEO and $STUB that’s how you stay in the game long term — not by marrying a ticker or arguing online. You can scroll posts all you want, but that doesn’t change the fact that disciplined traders survive cycles while emotional ones chase narratives. I’m here for the next move, not the last argument.

0 · Reply

carminefox Apr. 30 at 2:39 PM

$NEO good job with the earnings again! Just waiting on that buyout offer now.

0 · Reply

NeoGenomics to Participate in Upcoming Investor Conferences

2026-04-29T16:45:29.000Z - 16 days ago

NeoGenomics price target lowered to $11 from $13 at BofA

2026-04-29T13:42:05.000Z - 16 days ago

NeoGenomics price target raised to $14 from $13 at TD Cowen

2026-04-29T10:41:39.000Z - 16 days ago

Leerink upgrades NeoGenomics to Outperform, raises target to $25

2026-04-29T10:26:48.000Z - 16 days ago

NeoGenomics upgraded to Buy from Hold at Benchmark

2026-04-29T10:19:13.000Z - 16 days ago

NeoGenomics upgraded to Outperform from Market Perform at Leerink

2026-04-28T21:39:08.000Z - 16 days ago

NeoGenomics reports Q1 adjusted EPS 1c, consensus 0c

2026-04-28T21:36:36.000Z - 16 days ago

NeoGenomics raises FY26 revenue view to $797M-$803M from $793M-$801M

Apr 28, 2026, 4:30 PM EDT - 16 days ago

NeoGenomics Earnings Call Transcript: Q1 2026

Apr 28, 2026, 4:05 PM EDT - 16 days ago

NeoGenomics Reports First Quarter 2026 Results

2026-04-23T11:26:56.000Z - 22 days ago

NeoGenomics expands access to full oncology testing portfolio

Apr 23, 2026, 7:05 AM EDT - 22 days ago

NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

Apr 13, 2026, 7:05 AM EDT - 4 weeks ago

NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026

Apr 7, 2026, 7:05 AM EDT - 5 weeks ago

NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026

2026-03-16T11:28:54.000Z - 2 months ago

NeoGenomics PanTracer LBx test receives Medicare coverage

Mar 16, 2026, 7:05 AM EDT - 2 months ago

NeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling

Mar 10, 2026, 4:20 PM EDT - 2 months ago

NeoGenomics Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 1:10 PM EST - 2 months ago

NeoGenomics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 7:05 AM EST - 2 months ago

NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types

2026-02-24T11:47:07.000Z - 2 months ago

NeoGenomics price target raised to $13 from $12 at Piper Sandler

Feb 18, 2026, 7:05 AM EST - 3 months ago

NeoGenomics to Participate in Upcoming Investor Conferences

Feb 17, 2026, 8:30 AM EST - 3 months ago

NeoGenomics Earnings Call Transcript: Q4 2025

2026-02-17T12:45:49.000Z - 3 months ago

NeoGenomics sees FY26 adjusted EPS 16c-21c, consensus 19c

2026-02-17T12:40:53.000Z - 3 months ago

NeoGenomics reports Q4 adjusted EPS 6c, consensus 4c

Feb 17, 2026, 7:05 AM EST - 3 months ago

NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

Feb 12, 2026, 7:05 AM EST - 3 months ago

NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection

Jan 27, 2026, 7:05 AM EST - 3 months ago

NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

Jan 13, 2026, 8:15 PM EST - 4 months ago

NeoGenomics Transcript: 44th Annual J.P. Morgan Healthcare Conference

2026-01-12T12:38:01.000Z - 4 months ago

NeoGenomics reports preliminary Q4 revenue $190M, consensus $188.07M

2026-01-12T12:36:33.000Z - 4 months ago

NeoGenomics CFO Jeff Sherman to retire, Abhishek Jain to succeed

CDNA

Jan 12, 2026, 7:05 AM EST - 4 months ago

NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

2026-01-07T14:15:51.000Z - 4 months ago

NeoGenomics price target raised to $16 from $14 at TD Cowen

Jan 5, 2026, 7:05 AM EST - 4 months ago

NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 30, 2025, 7:05 AM EST - 4 months ago

NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors

2025-12-15T15:40:44.000Z - 5 months ago

NeoGenomics price target raised to $13 from $11 at BofA

2025-12-15T12:41:15.000Z - 5 months ago

NeoGenomics announce Natera withdrawal of appeal in patent litigation

NTRA

Dec 15, 2025, 7:05 AM EST - 5 months ago

NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation

Dec 10, 2025, 7:05 AM EST - 5 months ago

NeoGenomics to Present New ctDNA Research at SABCS 2025

Dec 8, 2025, 8:05 AM EST - 5 months ago

NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025

Dec 2, 2025, 2:30 PM EST - 5 months ago

NeoGenomics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 19, 2025, 2:00 PM EST - 6 months ago

NeoGenomics Transcript: Stephens Annual Investment Conference

Oct 30, 2025, 12:51 PM EDT - 7 months ago

NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors

Oct 28, 2025, 8:30 AM EDT - 7 months ago

NeoGenomics Earnings Call Transcript: Q3 2025

Oct 28, 2025, 7:05 AM EDT - 7 months ago

NeoGenomics Reports Third Quarter 2025 Results

Oct 14, 2025, 7:05 AM EDT - 7 months ago

NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025

Oct 7, 2025, 7:05 AM EDT - 7 months ago

NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025

Aug 29, 2025, 7:05 AM EDT - 9 months ago

Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera

Jul 30, 2025, 7:05 AM EDT - 10 months ago

NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy

Jul 29, 2025, 8:30 AM EDT - 10 months ago

NeoGenomics Earnings Call Transcript: Q2 2025

Jul 29, 2025, 7:05 AM EDT - 10 months ago

NeoGenomics Reports Second Quarter 2025 Results

Jul 1, 2025, 7:05 AM EDT - 11 months ago

NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

Jun 30, 2025, 7:05 AM EDT - 11 months ago

NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care

Jun 24, 2025, 7:05 AM EDT - 11 months ago

NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

Jun 4, 2025, 2:00 PM EDT - 1 year ago

NeoGenomics Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 1:00 PM EDT - 1 year ago

NeoGenomics Transcript: 45th Annual William Blair Growth Stock Conference

May 28, 2025, 7:10 AM EDT - 1 year ago

NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025

May 22, 2025, 7:10 AM EDT - 1 year ago

NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer

May 20, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics to Participate in Upcoming June Investor Conferences

May 1, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Pays Off 1.25% Convertible Senior Notes

Apr 29, 2025, 8:30 AM EDT - 1 year ago

NeoGenomics Earnings Call Transcript: Q1 2025

Apr 29, 2025, 8:00 AM EDT - 1 year ago

NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform

Apr 29, 2025, 7:30 AM EDT - 1 year ago

NeoGenomics Reports First Quarter 2025 Results

Apr 22, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting

Apr 8, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

Apr 7, 2025, 7:05 AM EDT - 1 year ago

NeoGenomics Completes Acquisition of Pathline

Apr 1, 2025, 7:05 AM EDT - 1 year ago

Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics

Mar 13, 2025, 9:00 AM EDT - 1 year ago

NeoGenomics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 11, 2025, 3:30 PM EDT - 1 year ago

NeoGenomics Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 7:00 AM EDT - 1 year ago

NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

Mar 4, 2025, 1:50 PM EST - 1 year ago

NeoGenomics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 18, 2025, 8:30 AM EST - 1 year ago

NeoGenomics Earnings Call Transcript: Q4 2024

Feb 18, 2025, 7:05 AM EST - 1 year ago

NeoGenomics Reports Fourth Quarter and Full Year 2024 Results

Jan 29, 2025, 8:05 AM EST - 1 year ago

NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025

Jan 15, 2025, 4:30 PM EST - 1 year ago

NeoGenomics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 7:05 AM EST - 1 year ago

NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan

Jan 10, 2025, 7:05 AM EST - 1 year ago

NeoGenomics Announces Chief Executive Officer Succession

Jan 6, 2025, 7:55 AM EST - 1 year ago

NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 8:05 AM EST - 1 year ago

NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma

Pavie99 May. 14 at 12:41 AM

$NEO donzo

0 · Reply

Kat_Harington May. 13 at 4:10 PM

$NEO inverse of market. If Nasdaq is up I know this will be down.

0 · Reply

EarningsInsider May. 12 at 2:45 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-neo-performance-materials-inc-stock-1/ $NEO Neo Performance Materials Earnings Trans

1 · Reply

proof851 May. 6 at 12:45 PM

$NEO long term holder

0 · Reply

OfficialStocktwitsUser May. 5 at 3:11 PM

0 · Reply

GordoHLYK13 May. 1 at 9:07 PM

0 · Reply

GordoHLYK13 May. 1 at 4:12 PM

$GNS $NEO $STUB My total gains so far in few weeks $GNS is just starting

0 · Reply

GordoHLYK13 May. 1 at 1:23 PM

$GNS check out Genius trying to be my Friday anchor next to $NEO and $STUB Pre market todays gains

0 · Reply

GordoHLYK13 Apr. 30 at 11:06 PM

0 · Reply

carminefox Apr. 30 at 2:39 PM

$NEO good job with the earnings again! Just waiting on that buyout offer now.

0 · Reply

GordoHLYK13 Apr. 30 at 11:10 AM

$GNS, $NEO , and $STUB—all in play. $GNS needs to step it up and keep pressure on. My portfolio is up 82% since last year and—added $GNS9K shares yesterday, just the start and feeling good This whole portfolio is built for upside. Let’s see it work. Not a big deal but feeling blessed

1 · Reply

Hashstockw Apr. 30 at 4:01 AM

$NEO and this is the second analyst in the last few days. The stock is still severely undervalued. https://www.marketbeat.com/instant-alerts/td-cowen-issues-positive-forecast-for-neogenomics-nasdaqneo-stock-price-2026-04-29/

0 · Reply

IN0V8 Apr. 29 at 4:40 PM

$NEO Buy Benchmark raises to buy from hold Leerink Partners raises target price to $25.00 from $12.00 Leerink Partners raises to outperform from market ?perform

0 · Reply

GordoHLYK13 Apr. 29 at 3:38 PM

$NEO

1 · Reply

GetVector Apr. 29 at 12:49 PM

Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves. VI will select up to 4 stocks per day. Today's VI stocks: $BE, $NEO, $STX, $VRNS.

0 · Reply

GordoHLYK13 Apr. 29 at 11:36 AM

$NEO

0 · Reply

GordoHLYK13 Apr. 29 at 11:17 AM

$NEO $EXAS $GH $NTRA $NEO move is no pump n dump — this is what a real fundamental breakout looks like. 🚀 NEO ripping premarket is a direct reaction to legit catalysts, not hype: 🔥 Q1 Earnings Beat • Revenue came in at $187M, beating Wall Street • Clinical revenue up 14% YoY • High-margin NGS revenue exploded 26% • Management RAISED 2026 guidance to $797M–$803M 🔥 Analyst Upgrades Rolling In • Leerink upgraded to Outperform and doubled PT from $12 to $25 • Benchmark also upgraded to Buy 🔥 MolDX Approval PanTracer liquid biopsy getting reimbursement support is a game changer — opens the door for recurring revenue and lowers risk big time. 💰 Heavy volume + better numbers + raised guidance + analysts chasing = smart money stepping in. This isn’t a pump… this is institutions repricing NEO higher. 📈

0 · Reply

ValueVester Apr. 28 at 10:23 PM

$NEO Finally. A quarter we can sink our teeth in.

0 · Reply

GordoHLYK13 Apr. 28 at 9:35 PM

$NEO $NEO just dropped a strong Q1 and bulls should be paying attention. 🔥 • Revenue beat at $187M, up 11% YoY • Core Clinical business growing strong at +14% • High-margin NGS exploding +26% • Full-year guidance RAISED to $797M-$803M • EBITDA up 27% to $9M • Adjusted net income turned positive 💰 • RaDaR ST launch opens a $20B market opportunity Yes, Pharma softness exists, but the money maker clinical side is carrying hard. Flat after-hours means Wall Street may still be sleeping on this one. If growth keeps stacking, $NEO could wake people up fast. 🦈📈

0 · Reply

AnyMonkey Apr. 28 at 9:31 PM

$NEO ok, ok earnings not bad. lets get moving again.

1 · Reply

StocktwitsEarnings Apr. 28 at 9:06 PM

$NEO Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.13 up 35.00% YoY • Reported revenue of $186.67M up 11.09% YoY • NeoGenomics anticipates capital expenditures for the year ending December 31, 2026, to be in the range of $30.0 million to $35.0 million, funded by cash and financing to support business growth.

0 · Reply

GordoHLYK13 Apr. 28 at 8:04 PM

$CYCU $NEO $STUB The Nasdaq compliance clock has officially been reset. Bulls held the $1 close, pressure eased, and $CYCU just bought itself breathing room. Now it’s about stacking strength from here. 🔥

0 · Reply

Market Cap	1.08B
Revenue (ttm)	727.33M
Net Income (ttm)	-108.03M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-14.85%
Debt to Equity Ratio	0.00

Volume	424,546
Avg Vol	2,038,210
Day's Range	N/A - N/A
Shares Out	130.21M
Stochastic %K	12%
Beta	1.81
Analysts	Strong Sell
Price Target	$15.05